Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, Japan

Biocon Biologics has entered into a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & Johnson to launch Bmab 1200, a biosimilar to Stelara, in Europe, the UK, Canada, and Japan. This deal resolves patent disputes and secures future market entry, pending regulatory approvals.